[Decrease of vascular fragility in diabetic retinopathy through calciumdobesilate (author's transl)].
D000328:Adult; D000368:Aged; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002198:Capillary Fragility / Q000187:drug effects*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D006873:Hydroquinones / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012171:Retinal Vessels / Q000187:drug effects; D013607:Tablets; D013997:Time Factors; D014785:Vision, Ocular / Q000187:drug effects
D001557:Benzenesulfonates; D006490:Hemostatics; D006873:Hydroquinones; D007004:Hypoglycemic Agents; D007328:Insulin; D010919:Placebos; D013607:Tablets
Gefässabdichtung bei diabetischer Retinopathie durch Kalziumdobesilat